H. Lundbeck (CPH:LUN) A New Pharmaceutical Candidate Lu AA38466 Enters Lundbeck's development Pipeline

H. Lundbeck (CPH:LUN) H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu AA38466 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans.

Lu AA38466 is an ion channel modulator and has demonstrated convincing effects in a number of animal models of neurological disorders.

"Focus at Lundbeck Research is to discover innovative compounds that address unmet needs for patients. Lu AA38466 is an example of a new generation of compounds with a great potential for treatment of certain neurological conditions," says Executive Vice President Peter Høngaard Andersen, Head of Research at Lundbeck.

Lundbeck contacts

Investors: Media:

Jacob Tolstrup Mads Kronborg Director Media Relations +45 36 43 30 79 +45 36 43 28 51

Palle Holm Olesen Head of Investor Relations +45 36 43 24 26

Release No 362 - 18 December 2008

About Lundbeck H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. In 2007, the company's revenue was DKK 11 billion (approximately EUR 1.5 billion or USD 2.0 billion). The number of employees is approx. 5,300 globally. For more information, please visit www.lundbeck.com.

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



LINK: http://hugin.info/130085/R/1278501/285242.pdf

H. Lundbeck

http://www.lundbeck.com

ISIN: DK0010287234

Stock Identifier: XCSE.LUN